RITUXIMAB
(Rituxan)Standard Prescription
rituximab __mg IV ___(frequency) (__mg/m2/dose)
Dosages
Children and adults:
Refer to specific treatment protocol.
The most common dosage regimen is 375 mg/m2/dose IV once weekly given by
slow IV infusion.
[Do not administer undiluted; do not administer as IV push or rapid IV infusion.]
Refer to specific treatment protocol.
The most common dosage regimen is 375 mg/m2/dose IV once weekly given by
slow IV infusion.
[Do not administer undiluted; do not administer as IV push or rapid IV infusion.]
Mechanism of Action
Anti-CD20 monoclonal antibody.
Forms Supplied
injection: 100 mg/vial, 500 mg/vial
Comments
Monoclonal antibody used to treat B cell lymphoma and post-transplant lymphoproliferative disease.
Has also been used to treat chronic, steroid-resistant Graft Versus Host Disease (GVHD), autoimmune hemolytic anemia, chronic immune thrombocytopenic purpura.
Infusion-related adverse effects include flu-like symptoms, fever, bronchospasm, hypotension, severe dyspnea, urticaria, angioedema and usually occur within 30-120 mins. Infusion-related adverse effects may occurup to 24 hrs after start of infusion.
Premedication with analgesic, antihistamine and/or corticosteroids may help prevent infusion-related reactions.
Other adverse effects may include neutropenia, lymphocytopenia, infections, hepatitis B and TB reactivation.
Has also been used to treat chronic, steroid-resistant Graft Versus Host Disease (GVHD), autoimmune hemolytic anemia, chronic immune thrombocytopenic purpura.
Infusion-related adverse effects include flu-like symptoms, fever, bronchospasm, hypotension, severe dyspnea, urticaria, angioedema and usually occur within 30-120 mins. Infusion-related adverse effects may occurup to 24 hrs after start of infusion.
Premedication with analgesic, antihistamine and/or corticosteroids may help prevent infusion-related reactions.
Other adverse effects may include neutropenia, lymphocytopenia, infections, hepatitis B and TB reactivation.
References
44
Last Edited
2022-04-23 07:25:30